26
March 2025
GenIP Plc
("GenIP"
or the "Company")
Contract
Win
GenIP Plc, a technology business
providing Generative Artificial Intelligence (GenAI) services to
help research organisations and corporations commercialise their
innovations, is pleased to announce it has secured a contract worth
approximately USD$65,000 with a Singapore-based research institute
(the "Client").
This contract, covering the delivery
of 100 GenAI-enhanced analytical assessments, is part of a wider
bid process with leading Asian institutions referred to in GenIP's
announcement 13 March 2025.
The award results from GenIP's
ongoing sponsorship of key technology transfer initiatives and
marketing activities in leading Southeast Asian technology
hubs.
Analytical assessment revenue will
be recognised upon report production by GenIP and delivery to the
Client.
Melissa Cruz, CEO of GenIP, commented:
"We are delighted to partner with a
leading research and innovation institution in Singapore to
accelerate the commercialisation of new technological discoveries.
This collaboration demonstrates the broad application of our
technology evaluation services by supporting cutting-edge clinical
and healthcare research and innovation. Furthermore, this contract
underscores the significant size of the addressable market for our
technology commercialisation services."
For
further information regarding GenIP, please visit
www.genip.ai, or
contact:
|
GenIP Plc
Melissa Cruz, CEO
|
|
Via Redchurch
Communications
|
|
|
|
|
|
Redchurch Communications (Financial PR)
John Casey
|
|
genip@weareredchurch.com
|
About Reach
announcements
This is a Reach announcement. Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute media only /
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on Reach.
